- Sobi reported a better-than-expected EBITA of SEK3.62 billion for the third quarter, surpassing the estimate of SEK3.21 billion.
- The EBITA margin stood at 47%, higher than the projected 41.1%.
- Revenue matched expectations with SEK7.78 billion.
- Elocta’s revenue fell short at SEK812 million, compared to the SEK887.2 million estimate.
- Alprolix revenue outperformed with SEK601 million, beating the expected SEK579.3 million.
- Kineret generated SEK769 million in revenue, above the anticipated SEK723.5 million.
- Orfadin’s revenue was below expectations at SEK109 million, against the SEK120.4 million forecast.
- Synagis revenue was reported at SEK11 million.
- Gamifant significantly outstripped expectations, bringing in SEK733 million versus the estimated SEK561.7 million.
- 2025 revenue is expected to grow at a low double-digit percentage at constant exchange rates.
- The adjusted EBITA margin for 2025 is projected to be in the mid-to-high 30s percentage of revenue.
- The investment community has issued 10 buy ratings, 4 holds, and 1 sell for Sobi’s stock.
Swedish Orphan Biovitrum AB on Smartkarma
Analyst coverage of Swedish Orphan Biovitrum AB on Smartkarma has been highlighted by Baptista Research. In their report titled “Swedish Orphan Biovitrum AB: Strategic Launches,” they delve into Sobi’s Q1 2025 results. Sobi, a pharmaceutical company focusing on rare diseases, showcased a mixed performance in the first quarter, revealing both financial metrics and qualitative insights during the earnings call. This analysis provides a detailed look at Sobi’s operations and strategic trajectory.
A look at Swedish Orphan Biovitrum AB Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 4 | |
| Resilience | 4 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Swedish Orphan Biovitrum AB (SOBI) is positioned for long-term growth and resilience, as indicated by its high scores in Growth, Resilience, and Momentum according to Smartkarma Smart Scores. With a focus on developing therapies for haemophilia, inflammation, and genetic diseases, SOBI’s innovative approach is driving its positive momentum within the industry.
While the company may have room for improvement in terms of its Dividend score, its solid Value score reflects a stable foundation. SOBI’s global reach and commitment to research and development highlight its potential for sustained success in the biopharmaceutical sector.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
